Volume 2, Issue 13, Part 3.
\nNestoras Mathioudakis, MD from Johns Hopkins interviews Dr. Marc Rendell from Creighton University School of Medicine about the study: Efficacy and Safety of MK-1293 Insulin Glargine Compared Along with Originator Insulin Glargine (Lantus) in Type 2 Diabetes, presented at the June 2016 American Diabetes Association Scientific Session.
\nThe post Efficacy and Safety of MK-1293 Insulin Glargine Compared with Originator Insulin Glargine (Lantus) in Type 2 Diabetes (T2D) appeared first on DKBmed Radio.
","author_name":"eDiabetes Review"}